Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
15.45 ^USD	-1.34%		-23.33%	-40.99%

Mar. 21	Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected	MT
Mar. 21	US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady	MT

Talaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022

November 10, 2022 at 07:12 am EST

Talaris Therapeutics, Inc. reported earnings results for the third quarter ended September 30, 2022. For the third quarter, the company reported net loss was USD 19.01 million compared to USD 12.94 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to USD 0.32 a year ago.

Latest news about Tourmaline Bio, Inc.

Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected	Mar. 21	MT
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady	Mar. 21	MT
Top Premarket Decliners	Mar. 21	MT
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027	Mar. 19	MT
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024	Mar. 19	CI
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing	Jan. 31	MT
Tourmaline Bio Prices $150 Million Common Stock Offering	Jan. 25	MT
Tourmaline Bio, Inc.(NasdaqGS:TRML) added to NASDAQ Biotechnology Index	Dec. 18	CI
Tourmaline Bio Joins Nasdaq Biotechnology Index	Dec. 15	MT
Jefferies Starts Coverage on Tourmaline Bio with Buy Rating, $41 Price Target	Dec. 15	MT
Tourmaline Bio, Inc. Appoints Clay Siegall to Serve as a Director	Dec. 14	CI
Tourmaline Bio, Inc. Announces Resignation of Cariad Chester as Member of the Board of Directors	Nov. 30	CI
Transcript : Tourmaline Bio, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 01:00 PM	Nov. 29
Truist Starts Tourmaline Bio With Buy Rating, $43 Price Target	Nov. 17	MT
North American Morning Briefing : Stock Futures -2-	Nov. 16	DJ
Talaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Transcript : Tourmaline Bio, Inc. Presents at Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference, Nov-06-2023 03:50 PM	Nov. 06
Tourmaline Bio Insider Bought Shares Worth $280,584, According to a Recent SEC Filing	23-10-27	MT
Tourmaline Bio Insider Bought Shares Worth $110,912, According to a Recent SEC Filing	23-10-26	MT
Piper Sandler Initiates Coverage on Tourmaline Bio with Overweight Rating, $65 Price Target	23-10-25	MT
Tourmaline Bio Closes Merger With Talaris Therapeutics	23-10-20	MT
Tourmaline Bio Completes Merger With Talaris Therapeutics	23-10-19	MT
Talaris Therapeutics, Inc.(NasdaqGM:TALS) dropped from NASDAQ Composite Index	23-10-19	CI

Chart Tourmaline Bio, Inc.

Duration

Period

More charts

Company Profile

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Companyâs initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.66 USD

Average target price

58.33 USD

Spread / Average Target

+272.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TOURMALINE BIO, INC.	-40.99%	402M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs